Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten research firms that are covering the firm, MarketBeat reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock […]
Pacira BioSciences (PCRX) Granted Regenerative Medicine Advance Therapy Designation for PCRX-201 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Pacira BioSciences, Inc. (PCRX) said the FDA has granted Regenerative Medicine Advanced Therapy designation to PCRX-201, the company's intra-articular helper-dependent adenovirus gene therapy product candidate that codes for interleukin-1 receptor antagonist, for the treatment of osteoarthritis of the knee.
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at JPMorgan Chase & Co. themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.